Negotiable: Paramount Recruitment: Support Bioinformatician Genomics, Permanent, Research Services Team! Paramount are working in partnership with Genomics England to help expand their team - after successfully completing the 100,000 Genomes Project recently they are working together London, England

Negotiable: Paramount Recruitment: Senior Scientist Machine Learning - Bioinformatics Senior level, permanent, Immunology! A fantastic new opportunity has become available for a Bioinformatics Scientist specialising in Machine Learning to join a biopharma company in Baden-Wuerttember Baden-Württemberg, Germany

Negotiable: Paramount Recruitment: Rare Disease Analyst - Permanent 100,000 Genomes Project - Bioinformatics - Central London Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Negotiable: Paramount Recruitment: Clinical Bioinformatician Bioinformatics, Permanent, Rare Diseases and Cancer! Paramount are working in partnership with Genomics England who have successfully completed their 100,000 Genomes Project and are now working with the NHS to create the w London, England

Funding Opportunity RFA-EB-18-002 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support non-commercial lab-to-user dissemination of novel, reliable imaging and bioengineering technologies, including devices, software, methods, chemical agents, etc. Proposed technologies should have been prototyped, validated, and are potentially highly impactful to the research community. However, their beyond-the-lab dissemination via commercialization or industry partnership is not anticipated. Projects should focus on transforming functioning prototypes to usable tools and delivering them to end users for high-quality research in a reliable manner. Related activities may include, but are not limited to, quality control, scale-up production, user training, and technical improvements that are within the scope of the prototyped technology and limited to applying proven techniques or existing resources. Projects that involve clinical trials, commercialization, academic-industry partnership, or service using existing equipment are not responsive to this FOA.

Funding Opportunity PAR-19-137 from the NIH Guide for Grants and Contracts. The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a clinical trial but are not required to (optional).

Competitive Salary: EMBL: Bioinformatics Cloud Architect Location: Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Bioinformatics Software Engineer Location: Cambridge, Cambridgeshire, England

Notice NOT-HL-18-665 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-135 from the NIH Guide for Grants and Contracts. The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduates Schools of Arts and Sciences is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools of arts and sciences to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

Funding Opportunity PAR-19-134 from the NIH Guide for Grants and Contracts. The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools of Arts and Sciences is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools of arts and sciences to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years.

Funding Opportunity PAR-19-136 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 1224 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Funding Opportunity PAR-19-133 from the NIH Guide for Grants and Contracts. The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

Funding Opportunity RFA-DA-19-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to take part in the creation of Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (SUDs). The purpose of this Funding Opportunity Announcement (FOA) is to support the creation of Laboratories with expertise and resources to conduct early clinical evaluation of potential pharmacotherapies for Substance Use Disorders (SUDs). The goal is to accelerate the clinical development of medications to treat Substance Use Disorders (SUDs) by supporting Laboratories with expertise and resources to timely and efficiently conducting FDA-defined Phase 1 and/or Phase 2 clinical trials of new or repurposed compounds to treat SUDs. the clinical development of medications to treat Substance Use Disorders (SUD) by supporting laboratories with the expertise and resources to timely and efficiently conduct early (Phase 1 or Phase 2) clinical trials of potential pharmacotherapies for SUDs.

Notice NOT-MH-19-006 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Data Scientists - Drug Discovery - Post-Doc Level One of the world's most prestigious pharmaceutical companies is expanding their drug discovery research facility and seeking a talented Bioinformatics, Data Scientists, Machine Learning Enthusiasts, Sta Oxfordshire, England

Negotiable: Paramount Recruitment: Bioinformatics Post-Docs - Cancer Diagnostics Paramount have two fantastic opportunities for Bioinformatics/Comp Bio/Data Science/Statistical Genetic Cambridge, England

Funding Opportunity RFA-DA-19-029 from the NIH Guide for Grants and Contracts. NIDA and the following NIH Institutes, Centers, and Programs, NIAAA, NICHD, NIMH, NIMHD, NINDS, and ECHO intend to publish a funding opportunity announcement to solicit applications to propose and test the feasibility of research study designs addressing the impact of pre- and postnatal substance exposure (including opioids, opioid treatment medications, cannabis, alcohol, tobacco, other prescription or illicit substances, alone or in combination) on brain, social, and behavioral development, mental illness, and substance use. In addition to planning and testing the feasibility of study designs, awardees will be expected to participate in several grantee meetings to share lessons learned and begin to develop the network of sites needed to conduct this study.

Funding Opportunity RFA-DA-19-036 from the NIH Guide for Grants and Contracts. NIDA and the following NIH Institutes, Centers, and Programs, NIAAA, NICHD, NIMH, NIMHD, NINDS, and ECHO intend to publish a funding opportunity announcement to solicit applications to propose and test the feasibility of research study designs addressing the impact of pre- and postnatal substance exposure (including opioids, opioid treatment medications, cannabis, alcohol, tobacco, other prescription or illicit substances, alone or in combination) on brain, social, and behavioral development, mental illness, and substance use. In addition to planning and testing the feasibility of study designs, awardees will be expected to participate in several grantee meetings to share lessons learned and begin to develop the network of sites needed to conduct this study.

Notice NOT-GM-19-007 from the NIH Guide for Grants and Contracts